A Phase 3 Randomized Open-label Study of Brigatinib (Alunbrig) Versus Alectinib (Alecensa) in Advanced Anaplastic Lymphoma Kinase-Positive Non Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Alectinib (Primary) ; Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors ARIAD Pharmaceuticals; Takeda
- 21 Jan 2019 Planned initiation date changed from 15 Jan 2019 to 15 Feb 2019.
- 19 Dec 2018 Planned initiation date changed from 15 Dec 2018 to 15 Jan 2019.
- 27 Jul 2018 New trial record